Tools & Assets

Explore the most promising technologies from our research laboratories.

Publications

Explore scientific publications straight from our research laboratories.

Key Opinion Leaders

Look no further for Scientific or Medical Expertise

Startups

Find your next strategic partnership or investment.

Vaccine Adjuvant (T-Vant)

T-Vant is a potent adjuvant developed by Tulane scientists. This isolated lipid nanoparticle can stimulate not only the B-Cells and CD4+ T-Cells usually associated with vaccine protection, these OMVs also stimulate a potent CD8+ T-cell response. This new technology is suitable for use with any microbe or antigen and has been tested in multiple virus and bacterial challenge models.

Publications

A novel outer membrane vesicle adjuvant improves vaccine protection against Bordetella pertussis View
Establishment of isotype-switched, antigen-specific B cells in multiple mucosal tissues using non-mucosal immunization View
An Outer Membrane Vesicle-Adjuvanted Oral Vaccine Protects Against Lethal, Oral Salmonella Infection View
Bacterial-Derived Outer Membrane Vesicles are Potent Adjuvants that Drive Humoral and Cellular Immune Responses View

Explore a Partnership

Flexible collaboration models available — Sponsored Research, Co-Development, Licensing.

For inquiries, contact:
Alexis Ducote, PhD
Business Development Associate
aducote@tulane.edu
337.540.4025

X

Schedule a call

Set up a meeting with one of our team members by using the Calendly integration below.

Is it urgent? Call us:

James Zanewicz (+1 504.919.3800),

Alexis Ducote (+1 337.540.4025),

Carolyn Scofield (+1 504.881.4542).